

Carolyn A Day

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9229312/publications.pdf>

Version: 2024-02-01

103
papers

1,932
citations

270111

25
h-index

340414

39
g-index

104
all docs

104
docs citations

104
times ranked

2442
citing authors

#	ARTICLE	IF	CITATIONS
1	Operationalising cultural competency in the context of substance use treatment: a qualitative analysis. <i>Drugs: Education, Prevention and Policy</i> , 2022, 29, 76-84.	0.8	3
2	Client resistance to hepatitis C treatment initiation in opioid agonist treatment clinics in Sydney, Australia: A qualitative study. <i>Drug and Alcohol Review</i> , 2022, 41, 706-714.	1.1	2
3	A comment on participant reimbursement within Australian drug and alcohol research. <i>Drug and Alcohol Review</i> , 2022, , .	1.1	3
4	Setting foot in private spaces: extending the hepatitis C cascade of care to automatic needle/syringe dispensing machines, a mixed methods study. <i>Harm Reduction Journal</i> , 2022, 19, .	1.3	1
5	The impact of a 24-hour syringe dispensing machine on a face-to-face needle and syringe program and targeted primary healthcare clinic. <i>Australian and New Zealand Journal of Public Health</i> , 2022, 46, 524-526.	0.8	0
6	What are people saying on social networking sites about the Australian alcohol consumption guidelines?. <i>Medical Journal of Australia</i> , 2021, 214, 105.	0.8	2
7	Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia. <i>Harm Reduction Journal</i> , 2021, 18, 20.	1.3	27
8	Should we be using e-vouchers to compensate research participants? Acceptability among opioid agonist treatment clients. <i>Drug and Alcohol Review</i> , 2021, 40, 1356-1357.	1.1	2
9	Developing a model of care for substance use in pregnancy and parenting services, Sydney, Australia: Service provider perspectives. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108420.	1.5	2
10	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. <i>Addiction</i> , 2021, 116, 1482-1494.	1.7	3
11	Assessing Drug Consumption Rooms and Longer Term (5 Year) Impacts on Community and Clients. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 4639-4647.	1.2	5
12	Safer injecting facilities" is the research there? A comment on Caulkins et al . (2019). <i>Addiction</i> , 2020, 115, 784-785.	1.7	2
13	Health and social interventions in the context of support and control: The experiences of marginalised people who use drugs in Australia. <i>Health and Social Care in the Community</i> , 2020, 28, 1152-1159.	0.7	6
14	Gender-Specific Online Content Is Important and Timely for Women Receiving Treatment for Substance Use Disorders. <i>Journal of Women's Health</i> , 2020, 29, 605-606.	1.5	2
15	Integration of a contraception clinic into an opioid treatment setting to improve contraception knowledge, accessibility and uptake: a pilot study. <i>Australian and New Zealand Journal of Public Health</i> , 2020, 44, 360-362.	0.8	5
16	Youth Practitioners™ Perspectives on Building Agency and Supporting Transitions with and for Young People Experiencing Disadvantage. <i>Journal of Applied Youth Studies</i> , 2020, 3, 293-310.	0.9	8
17	Alcohol treatment systems in Muslim majority countries: Case study of alcohol treatment policy in Iran. <i>International Journal of Drug Policy</i> , 2020, 80, 102753.	1.6	8
18	Asking young Aboriginal people who use illicit drugs about their healthcare preferences using audio-computer-assisted self-interviewing. <i>Drug and Alcohol Review</i> , 2019, 38, 482-493.	1.1	3

#	ARTICLE	IF	CITATIONS
19	“Beyond Safer Injecting” Health and Social Needs and Acceptance of Support among Clients of a Supervised Injecting Facility. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2032.	1.2	5
20	Alcohol policy in Iran: Policy content analysis. <i>International Journal of Drug Policy</i> , 2019, 73, 185-198.	1.6	19
21	Overdose Risk and Client Characteristics Associated With the Injection of Buprenorphine at a Medically Supervised Injecting Center in Sydney, Australia. <i>Substance Use and Misuse</i> , 2019, 54, 1646-1653.	0.7	4
22	Identification of smoking status in the Census is needed, but what about the healthcare system?. <i>Australian and New Zealand Journal of Public Health</i> , 2019, 43, 96.	0.8	0
23	Drug consumption rooms: A systematic review of evaluation methodologies. <i>Drug and Alcohol Review</i> , 2019, 38, 406-422.	1.1	26
24	Challenges faced with opioid prescriptions in the community setting – Australian pharmacists’ perspectives. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 966-973.	1.5	9
25	Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health care system. <i>Drug and Alcohol Review</i> , 2019, 38, 264-269.	1.1	21
26	Developing a model of care for Substance Use in Pregnancy and Parenting Services in Sydney, Australia. <i>International Journal of Integrated Care</i> , 2019, 19, 141.	0.1	0
27	A managed alcohol program in Sydney, Australia: Acceptability, cost savings and non-beverage alcohol use. <i>Drug and Alcohol Review</i> , 2018, 37, S184-S194.	1.1	20
28	Vertical transmission of hepatitis C: Testing and health care engagement. <i>Journal of Paediatrics and Child Health</i> , 2018, 54, 647-652.	0.4	6
29	Prescription Opioid Misuse and Public Health Approach in Australia. <i>Substance Use and Misuse</i> , 2018, 53, 200-205.	0.7	20
30	The need for more research and considered debate regarding women-only treatment services: a comment on Neale et al. (2018). <i>Addiction</i> , 2018, 113, 1752-1752.	1.7	2
31	Smoking in Correctional Settings Worldwide: Prevalence, Bans, and Interventions. <i>Epidemiologic Reviews</i> , 2018, 40, 82-95.	1.3	49
32	Women Need Less Judgment and More Support to Access Contraception. <i>Journal of Women's Health</i> , 2018, 27, 1187-1188.	1.5	0
33	Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia. <i>International Journal of Drug Policy</i> , 2017, 47, 102-106.	1.6	15
34	Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. <i>Journal of Addiction Medicine</i> , 2017, 11, 10-18.	1.4	9
35	Estimating the number of people who inject drugs in Australia. <i>BMC Public Health</i> , 2017, 17, 757.	1.2	38
36	Has the Experience of Hepatitis C Diagnosis Improved Over the Last Decade? An Analysis of Canadian Women’s Experiences. <i>Canadian Journal of Nursing Research</i> , 2016, 48, 21-28.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Improving Access to Long-Acting Contraceptive Methods and Reducing Unplanned Pregnancy among Women with Substance Use Disorders. <i>Substance Abuse: Research and Treatment</i> , 2016, 10s1, SART.S34555.	0.5	24
38	Extent of alcohol prohibition in civil policy in Muslim majority countries: the impact of globalization. <i>Addiction</i> , 2016, 111, 1703-1713.	1.7	66
39	Civil alcohol policy in Muslim majority countries: need for global tools, expert support and local partnerships. <i>Addiction</i> , 2016, 111, 1718-1719.	1.7	2
40	Reluctance to Accept Alcohol Treatment by Alcoholic Liver Disease Transplant Patients: A Qualitative Study. <i>Transplantation Direct</i> , 2016, 2, e104.	0.8	19
41	The policy and practices of New South Wales drug treatment providers in responding to the possession of illicit substances on premises. <i>Drug and Alcohol Review</i> , 2016, 35, 644-649.	1.1	1
42	The impact of an automatic syringe dispensing machine in inner-city Sydney, Australia: No evidence of a "honey-pot" effect. <i>Drug and Alcohol Review</i> , 2016, 35, 637-643.	1.1	8
43	Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. <i>Addiction</i> , 2016, 111, 311-319.	1.7	63
44	Community attitudes towards harm reduction services and a newly established needle and syringe automatic dispensing machine in an inner-city area of Sydney, Australia. <i>International Journal of Drug Policy</i> , 2016, 27, 121-126.	1.6	11
45	Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial. <i>Journal of Clinical Virology</i> , 2016, 74, 66-72.	1.6	11
46	Senior nurses' perspectives on the transfer of opioid substitution treatment clients from clinics to community pharmacy. <i>Drug and Alcohol Review</i> , 2015, 34, 495-498.	1.1	2
47	New Understandings of Mothering: Mothers in an Abstinence-Based Drug Treatment Program. <i>International Journal of Mental Health and Addiction</i> , 2015, 13, 173-184.	4.4	11
48	Hepatitis B vaccination for people who inject drugs. <i>Lancet, The</i> , 2015, 385, 115.	6.3	2
49	The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. <i>International Journal of Drug Policy</i> , 2015, 26, 1094-1102.	1.6	18
50	Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. <i>International Journal of Drug Policy</i> , 2015, 26, 992-998.	1.6	65
51	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. <i>International Journal of Drug Policy</i> , 2015, 26, 976-983.	1.6	44
52	The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia. <i>Journal of Substance Abuse Treatment</i> , 2015, 58, 90-94.	1.5	12
53	Feasibility of ambulatory withdrawal management delivered in a NSW drug health service and correlates of completion. <i>Australian Health Review</i> , 2014, 38, 186.	0.5	0
54	Experiences of mothers with substance dependence: Informing the development of parenting support. <i>Journal of Clinical Nursing</i> , 2014, 23, 2835-2843.	1.4	16

#	ARTICLE	IF	CITATIONS
55	Hepatitis C testing and status among opioid substitution treatment clients in New South Wales. Australian and New Zealand Journal of Public Health, 2014, 38, 160-164.	0.8	9
56	Overview of Substance Use and Treatment from Australia. Substance Abuse, 2014, 35, 304-308.	1.1	8
57	Self-perceived problem with alcohol use among opioid substitution treatment clients. Addictive Behaviors, 2013, 38, 2018-2021.	1.7	11
58	Opioid substitution therapy clients' preferences for targeted versus general primary health care outlets. Drug and Alcohol Review, 2013, 32, 211-214.	1.1	9
59	Defining a service for people who use drugs as "low-threshold": What should be the criteria?. International Journal of Drug Policy, 2013, 24, 220-222.	1.6	37
60	A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Preventive Medicine, 2013, 57, 297-303.	1.6	54
61	Are primary health care centres that target injecting drug users attracting and serving the clients they are designed for? A case study from Sydney, Australia. International Journal of Drug Policy, 2013, 24, 326-332.	1.6	15
62	Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs in the Opioid Substitution Setting: ETHOS Study. Clinical Infectious Diseases, 2013, 57, S62-S69.	2.9	97
63	Sexually transmitted infections, sexual risk behaviours and perceived barriers to safe sex among drug users. Australian and New Zealand Journal of Public Health, 2013, 37, 311-315.	0.8	10
64	General health of opioid substitution therapy clients. Internal Medicine Journal, 2013, 43, 1335-1338.	0.5	15
65	Healthcare utilisation and disclosure of injecting drug use among clients of Australia's needle and syringe programs. Australian and New Zealand Journal of Public Health, 2013, 37, 148-154.	0.8	28
66	Factors influencing pharmacy services in opioid substitution treatment. Drug and Alcohol Review, 2013, 32, 426-434.	1.1	37
67	The cost of providing primary health care services from a needle and syringe program: A case study. Drug and Alcohol Review, 2013, 32, 312-319.	1.1	4
68	The reliability of sensitive information provided by injecting drug users in a clinical setting: Clinician-administered versus audio computer-assisted self-interviewing (ACASI). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2012, 24, 1496-1503.	0.6	69
69	Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. Journal of Substance Abuse Treatment, 2012, 43, 440-445.	1.5	28
70	Correlates of Susceptibility to Hepatitis B among People Who Inject Drugs in Sydney, Australia. Journal of Urban Health, 2012, 89, 769-778.	1.8	13
71	The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: A narrative synthesis of literature. International Journal of Drug Policy, 2012, 23, 94-102.	1.6	87
72	Primary healthcare outlets that target injecting drug users: Opportunity to make services accessible and acceptable to the target group. International Journal of Drug Policy, 2012, 23, 109-110.	1.6	8

#	ARTICLE	IF	CITATIONS
73	Effect of pegylated interferon- α 2a treatment on mental health during recent hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 957-965.	1.4	38
74	Individual versus team-based case management for clients of opioid treatment services: An initial evaluation of what clients prefer. <i>Drug and Alcohol Review</i> , 2012, 31, 499-506.	1.1	7
75	Fifteen years of HIV surveillance among people who inject drugs: the Australian Needle and Syringe Program Survey 1995-2009. <i>Aids</i> , 2011, 25, 835-842.	1.0	22
76	Development of a nurse-led primary healthcare service for injecting drug users in inner-city Sydney. <i>Australian Journal of Primary Health</i> , 2011, 17, 10.	0.4	21
77	Commentary on Turner et al. (2011): Significant global scale-up of harm reduction interventions and pragmatic research approaches needed to prevent hepatitis C transmission. <i>Addiction</i> , 2011, 106, 1989-1990.	1.7	0
78	A primary healthcare clinic in a needle syringe program may contribute to HIV prevention by early detection of incident HIV in an injecting drug user. <i>Australian and New Zealand Journal of Public Health</i> , 2011, 35, 294-295.	0.8	5
79	Harm reduction healthcare: From an alternative to the mainstream platform?. <i>International Journal of Drug Policy</i> , 2010, 21, 131-133.	1.6	23
80	The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. <i>Addiction</i> , 2010, 105, 329-334.	1.7	20
81	Forming a national multicentre collaboration to conduct clinical trials: Increasing high-quality research in the drug and alcohol field. <i>Drug and Alcohol Review</i> , 2010, 29, 469-474.	1.1	6
82	Hepatitis B virus among injecting drug users in Sydney, Australia: Prevalence, vaccination and knowledge of status. <i>Drug and Alcohol Dependence</i> , 2010, 108, 134-137.	1.6	22
83	Sexual and injecting risk behaviours among regular ecstasy users. <i>Addictive Behaviors</i> , 2010, 35, 157-160.	1.7	9
84	Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users. <i>Health Promotion Journal of Australia</i> , 2009, 20, 234-240.	0.6	9
85	Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: A review. <i>Drug and Alcohol Review</i> , 2009, 28, 669-675.	1.1	27
86	Clinical trial literacy among injecting drug users in Sydney, Australia: A pilot study. <i>Contemporary Clinical Trials</i> , 2009, 30, 431-435.	0.8	12
87	Acceptability of hepatitis C virus testing methods among injecting drug users. <i>Drug and Alcohol Review</i> , 2008, 27, 666-670.	1.1	22
88	Blood-borne virus prevalence and risk among steroid injectors: Results from the Australian Needle and Syringe Program Survey. <i>Drug and Alcohol Review</i> , 2008, 27, 559-561.	1.1	29
89	Injecting drug users' understanding of hepatitis C. <i>Addictive Behaviors</i> , 2008, 33, 1602-1605.	1.7	41
90	Representativeness of Injecting Drug Users Who Participate in HIV Surveillance. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 632-638.	0.9	38

#	ARTICLE	IF	CITATIONS
91	An examination of the quality of life among rural and outer metropolitan injecting drug users in NSW, Australia. <i>Addiction Research and Theory</i> , 2008, 16, 607-617.	1.2	10
92	Impact of Drug Market Changes on Substance-Using Pregnant Women in Three Key Sydney Drug Markets. <i>Women and Health</i> , 2007, 44, 93-105.	0.4	2
93	Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia. <i>Drug and Alcohol Dependence</i> , 2006, 83, 210-217.	1.6	20
94	Correlates of hepatitis C testing among heroin injectors in Sydney. <i>Health Promotion Journal of Australia</i> , 2006, 17, 70-72.	0.6	9
95	Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. <i>Harm Reduction Journal</i> , 2006, 3, 2.	1.3	47
96	The "lessons" of the Australian "heroin shortage". <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2006, 1, 11.	1.0	47
97	Patterns of drug use and associated harms among rural injecting drug users: Comparisons with metropolitan injecting drug users. <i>Australian Journal of Rural Health</i> , 2006, 14, 120-125.	0.7	52
98	Documenting the heroin shortage in New South Wales. <i>Drug and Alcohol Review</i> , 2006, 25, 297-305.	1.1	21
99	Changes in the initiation of heroin use after a reduction in heroin supply. <i>Drug and Alcohol Review</i> , 2006, 25, 307-313.	1.1	30
100	Identification and quantification of change in Australian illicit drug markets. <i>BMC Public Health</i> , 2006, 6, 200.	1.2	7
101	The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia. <i>BMC Public Health</i> , 2005, 5, 84.	1.2	8
102	Hepatitis C-related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination?. <i>Drug and Alcohol Review</i> , 2003, 22, 317-321.	1.1	77
103	Poor knowledge and low coverage of hepatitis B vaccination among injecting drug users in Sydney. <i>Australian and New Zealand Journal of Public Health</i> , 2003, 27, 558.	0.8	9